Oral orforglipron passes its heart-safety test against glargine

Design

Phase 3, randomised, open-label, event-driven non-inferiority trial

Population

2,749 adults with type 2 diabetes and established cardiovascular or kidney disease

Primary outcome

Time to four-component MACE

Effect

4.2% vs 5.0%; HR 0.84 (95% CI 0.59–1.20), non-inferior

ACHIEVE-4 enrolled 2,749 adults with type 2 diabetes, HbA1c 7.0–10.5% and a BMI of 25 or more, all with established cardiovascular or chronic kidney disease. They were randomised to once-daily oral orforglipron at the highest tolerated dose or titrated insulin glargine. The trial was open-label and event-driven, designed to rule out excess cardiovascular harm.

Over a median of two years, major cardiovascular events occurred in 4.2% on orforglipron and 5.0% on glargine (HR 0.84, 95% CI 0.59–1.20). The upper bound sat well under the 1.8 safety margin. Severe or clinically significant hypoglycaemia was far less common: 6.8% versus 19.2%. Gastrointestinal events affected 62% versus 14% and were the main reason people stopped orforglipron. Deaths were 1.4% versus 3.2%, though the trial was not designed to test that.

This matters because an oral, non-peptide GLP-1 agonist could reach patients who will not inject or cannot keep injectables cold. It establishes safety, not cardiovascular benefit: unlike injectable semaglutide or dulaglutide, there is no superiority result here. Orforglipron's approval status in India is unknown.

• For high-risk patients reluctant to start insulin, an oral GLP-1 agonist is becoming a realistic alternative.
• Expect fewer hypoglycaemic episodes than with basal insulin; worth discussing with patients who fear lows.
• Warn about gastrointestinal effects; they were the commonest reason to stop.
• Where proven cardiovascular benefit is the goal, injectable agents with outcome data remain the evidence-based choice.
• Check local availability before planning around it; regulatory status in India is unknown.

Why it matters

An oral drug with insulin-level glucose lowering and a clean heart-safety result changes what you can offer injection-averse patients.

Don't overread it

This is a safety result; it does not show orforglipron reduces cardiovascular events.

The statistics, in plain English

Non-inferiority means the trial set out to show orforglipron is not meaningfully worse. The hazard ratio of 0.84 leans in its favour, but the interval runs from 0.59 to 1.20 and crosses 1, so it does not show benefit. Open-label design can influence how adverse events are reported, though less so for hard cardiovascular events.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.